A weird and potentially nasty pattern in biotech because of the incentives it generates: A company's assets are IPO'ed, VCs make a pile of money,but when taken to Phase III they flop (Stemcentrx, Unity, Sirtris).It may be obvious to bio veterans,but flops should be easier to spot
-
-
Agreed. Don’t worry I think blockchains can keep track of who contributed what

-
Once we have nanoparticle-delivered minichips and we are running ethereum nodes in our cells it'll all sort itself out
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.